No Data
No Data
Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?
H.C. Wainwright Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $64
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
Express News | As Consideration For Assets, UroGen Issued IconOVir 374,843 Of Its Ordinary Shares, Agreed To One-Time Payment Of $15M Upon Milestones And A Low Single-Digit Royalty Percentage
Express News | UroGen Acquires Assets Relating To ICVB-1042 From IconOVir
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations